Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant add-on to somatostatin analogs in acromegaly
NL-OMON39522Not yet recruiting
- Sponsor
- Dept. of Medicine, Erasmus University MC Department of Endocrinology and Metabolism, Leiden University Medical Center
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of pegvisomant in acromegaly, sponsored by Dept. of Medicine, Erasmus University MC Department of Endocrinology and Metabolism, Leiden University Medical Center. Primary endpoints: Change in quality of life over 16 weeks and Change in AcroQoL physical score. Planned start Sep 2013; status: not yet recruiting.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON39522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39522.